Background Providing renal support for small children is very challenging using the machinery currently available in the United States. As the extracorporeal volume (ECV) relative to blood volume increases and the state of critical illness worsens, the chance for instability during continuous renal replacement therapy (CRRT) initiation also increases. CRRT machines with smaller ECV could reduce the risks and improve outcomes. Methods We present a case series of small children (n=12) who received continuous venovenous hemofiltration (CVVH) via an Aquadex™ machine (ECV=33 ml) with 30 ml/kg/h of prereplacement fluids at Children's of Alabama between December 2013 and April 2015. We assessed in vitro fluid precision using the adapted continuous veno-venous hemofiltration (CVVH) system. Results We used 101 circuits over 261 days to provide CVVH for 12 children (median age 30 days; median weight 3.4 kg). Median CVVH duration was14.5 days [interquartile range (IQR)=10; 22.8 days]. Most circuits were routinely changed after 72 h. Five of 101 (5 %) initiations were associated with mild transient change in vital signs. Complications were infrequent (three transient cases of hypothermia, three puncturesite bleedings, one systemic bleed, and one right atrial thrombus). Most patients (7/12, 58 %) were discharged from the intensive care unit; six of them (50 %) were discharged home. Conclusions CRRT machines with low ECV can enable clinicians to provide adequate, timely, safe, and efficient renal support to small, critically ill infants.
Introduction
Despite rates of acute kidney injury (AKI) being higher than most critically ill nephrology populations [1] , neonates infrequently receive renal support. The technical challenges of traditional machines make continuous renal replacement therapy (CRRT) initiation very difficult, even at experienced tertiary children's hospitals. In the United States, the smallest CRRT circuit is~100 ml (i.e., Prismaflex M60), and no circuits are approved by the US Food and Drug Administration (FDA) for use in children <20 kg. Some centers have eliminated this circuit from use at their institutions due to the bradykinin release response that has been seen in filters using an AN-69 membrane; instead, they have chosen to only provide therapy with a circuit with an extracorporeal volume (ECV) of 165 ml. Some centers do not offer CRRT to any infant, let alone for critically ill or premature infants, because of the inherent risk of initiation. When used, these larger machines necessitate that small children receive CRRT with proportionally larger filters, higher blood flows, massive clearance rates, and big vascular catheters compared with bigger children [2] . Priming the CRRT circuit with blood reduces morbidity; yet blood primes are not without risk, as they can cause acidosis, hypocalcemia, hyperkalemia, thrombocytopenia, hypotension, and coagulopathy, especially as the percentage ECV to patient blood volume increases. These complications and the need to alter the CRRT prescription stem from the markedly large ECV inherent in available machinery.
Despite protocols to reduce the risk of CRRT in small patients-using fresh packed red blood cells (pRBCs), diluting them to a more physiologic hematocrit, normalizing pH with sodium bicarbonate, and giving calcium IV to counteract the low-ionized calcium-the initiation of CRRT therapy has historically been fraught with anxiety and hemodynamic compromise in small infants. In our experience, the higher the percent ECV and the more critically ill the patient is before initiation, the more likely problems will arise as a consequence of CRRT initiation. Using the Pediatric Prospective Continuous Renal Replacement Therapy (ppCRRT) registry, which includes 13 centers and >350 children on CRRT, we showed that children <10 kg have a significantly lower survival rate than children who are >10 kg (33 vs. 67 %; p<0.05) [2] . The lower rates of survival are perhaps due to patient selection, initiation of CRRT only as Blast resort^, the added risks of circuit initiation, or a combination of these factors. We and others have suggested that CRRT machines with smaller ECV could reduce the risks associated with therapy and improve outcomes.
Several groups have begun to develop dialysis and convective-clearance devices that use a smaller circuit. Two machines have been designed specifically for small infants: the Newcastle Infant Dialysis Ultrafiltration System (NIDUS), which has an ECV of 6.5 ml for filters of 0.045 m 2 , and the Cardiac And Renal Pediatric Dialysis Emergency (CARPEDIEM™) that has available circuits of 27, 34, and 45 ml for filters of 0.075, 0.15, and 0.25 m 2 [3, 4] . However, because these machines are not available in the United States, pediatric nephrologists who are faced with a small child in need of renal support therapy must either use CRRT machines with high ECV, or deny their patients proper renal support therapy.
To mitigate concerns posed by CRRT machines with large ECV in relation to blood volume size, we adapted the Aquadex™ machine to provide prefilter replacement fluids to allow for continuous venovenous hemofiltration (CVVH). In 2007, the US Food and Drug Administration (FDA) approved the use of the Aquadex™ machine for ultrafiltration (UF) of plasma volume in adults with heart failure who did not respond to diuretic therapy. We adapted this machine to help improve the ability to initiate CRRT in small children who require renal support at our institution. We designed policies and procedures; trained physicians, dialysis nurses, and bedside nurses on its use; and began this therapy in December 2013. As for any other renal support therapy procedure, we designed the procedure with the goals of maintaining electrolyte and water homeostasis as well as clearing waste products while minimizing risks, particularly during CRRT initiation. In this report, we describe how we adapted the machine, report in vitro data documenting the system's fluid precision, and describe the first 12 infants who received CVVH at our institution using the Aquadex™ machine.
Methods Procedure
The Aquadex™ circuit (Baxter Corporation, Minneapolis, MN, USA) has a 33-ml volume when using the UF 500 filter set with the hematocrit (HCT) monitor. A roller pump provides negative pressure through the withdraw (access) line to bring blood from the patient to the hemofilter. A second pump provides negative pressure on the hemofilter to remove plasma volume. The filter is 0.12 m 2 and is composed of polysulfone membranes. The sieving coefficients for urea, creatinine, vitamin B 12 , and albumin are 0.98, 0.98, 0.98, and <0.02, respectively. Blood is returned via an inlet (return) line to the patient. The circuit has an in-line continuous HCT sensor, and there is software in place to automatically stop removing fluid if the HCT hits the prescribed limit. The tubing set has pigtails before and after the filter. The blood pump can run at 10-40 ml/min (at intervals of 5) and has an accuracy of +15-20 % of setting for withdrawal pressure of 250 mmHg. The UF pump has a range of 0-500 ml/h in 10-ml/h increments and an accuracy of ±10 % of setting. The machine has an air detector and a blood-leak detector. The operational range for the access, return (infusion), and UF (transmembrane) pressures is −350 to 500 mmHg. UF rates of up to 500 ml/h in CVVH mode are ample to clear waste products in small children; no port is present to provide countercurrent dialysis (Aquadex™ Flex Flow User Guide).
The schematic for the machine in CVVH mode is shown in Fig. 1 . Venous access is placed by the surgical or intensive care team in consultation with the pediatric nephrologist. Blood flow rate is titrated to 40 ml/min. A y-connector is placed on the access line to provide continuous heparin administration for anticoagulation. Prefilter replacement fluid is infused with an Alaris™ (head unit model #8015; large volume pump module #8100) fluid infusion system via the proximal pigtail of the circuit. Anticoagulation monitoring is obtained from the distal pigtail of the circuit. Heparin infusion rate is titrated to activated clotting time (ACT) goals specified by the team. We initially set the target ACT for 180-220 s, later reducing it to 160-180 s. UF rates are adjusted to match the intake of the previous hour, in addition to the prescribed amount to Bleave on^or Btake off.^A blood warmer (AstoFlo Plus™ Stihler Electronic, Stuttgart, Germany) is placed on the infusion line. The hematocrit limit is set to 50 %. Circuits run continuously and must be changed out every 72 h.
Circuits are primed with pRBCs or saline according to our institution's guidelines. Therefore, in accordance with institutional protocols, if a patient has <10 % of ECVand is clinically stable, a saline prime is used; if a patient has an ECV ≥10 %, the circuit is primed with pRBCs. To get pRBC close to being physiologic, the blood prime is diluted 1:1 with sodium bicarbonate (to correct low pH and decrease HCT), and 1 ml of 10 % calcium gluconate is infused (to compensate for the low ionized calcium level of banked blood), as we previously described [5] . If criteria for blood prime is met and the circuit runs for 72 h or a planned circuit change occurs, we crossprime the new circuit with blood of the expiring circuit, according to institutional protocols.
In vitro assessment of fluid accuracy
We performed in vitro experiments to determine fluid precision using the adapted CVVH system. We tested three different access pressure conditions (−50, −125, and −200 mmHg) and three different replacement-fluid flow rates (100, 300, and 500 ml/h). Each set of conditions was performed in triplicate for a total of 27 individual runs. We calculated percentage of error as follows: % error=(delivered−prescribed)/delivered, where the amount delivered was calculated by subtracting the weight of the bag before infusion from the weight of the bag after infusion. We examined differences in fluid precision by pressure and fluid-flow differences. Because data was nonnormally distributed and we were comparing three groups, we used the Kruskal-Wallis test to compare differences among groups. We then compared differences between groups using Tukey's test. For all analyses, a p value <0.05 was considered statistically significant.
Results

Case series
We performed a case series on all children (12) who received CVVH using the adapted Aquadex™ system between December 2013 and April 2015 at Children's of Alabama Hospital, Birmingham, AL, USA. Informed consent for CRRT was obtained after the benefits and risks were discussed with the family, in accordance with policies for all acute RRT procedures (hemodialysis, peritoneal dialysis, CRRT) at our institution. The University of Alabama at Birmingham Institutional Review Board approved this retrospective report of the case series, with waiver of informed research consent. Data was extracted from our electronic medical records and the CRRT clinical quality improvement database.
The decision to initiate CRRT, as well as machine and access type, were determined by the pediatric nephrologist in consultation with the intensive care team. In general, Aquadex™ was chosen if the child was <15 kg, peritoneal dialysis (PD) was contraindicated, and/or the patient already had vascular access established (e.g., if the patient had a catheter for extracorporeal membrane oxygenation). We excluded the use of the Aquadex system for any infants who needed CRRT because of inborn errors of metabolism, as they would require much higher clearance rates during CRRT [6] .
Characteristics of the 12 patients who received CVVH are listed in Table 1 . For the most part, these were very critically ill children for whom the only options we had for renal support were CVVH with Aquadex™ or continuous venovenous hemodiafiltration (CVVHDF) with Prismaflex™. The median age at initiation was 30 days [minimum=4 days; maximum= 4 years; interquartile range (IQR)= 13-38 days). Median weight at initiation was 3.4 kg (minimum=2.7 kg; maximum=12.4 kg; IQR=3.0, 4.3 kg). Indications for CRRT were severe congenital chronic kidney disease (with a contraindication for peritoneal dialysis; n=3) and acute kidney injury (n=9). Median percentage of fluid overload [defined as fluid intake-fluid output/intensive care unit (ICU) admission weight] at CRRT initiation was 25.5 % (IQR=9.5, 38.5). Infants received care in the children's ICU (CICU) (n=5) or the neonatal ICU (NICU) (n=7). Most children had double-lumen Heparin is infused through a y-connector attached to the withdraw (access) line of the patient's catheter. Using an in-line medication infusion machine, prereplacement fluid is infused via the proximal pigtail of the circuit. There are two pumps on the machine, the blood pump (which can pump blood to a maximum of 40 ml/min), and the ultrafiltration (UF) pump (which can perform UF to a maximum of 500 ml/h when the blood flow is 40 ml/min). Blood for anticoagulation monitoring is obtained through the distal pigtail of the circuit. A blood warmer is attached to the tubing on the infusion (return) line before the blood it is returned to the patient eGFR was calculated using Schwartz formula (0.41×ht cm/creatinine mg/dl) Wt weight, FO fluid overload, CVVH continuous venovenous hemofiltration, PUV posterior uretheral valves, PPHN persistent pulmonary hypertension, ECMO extracorporeal membrane oxygenation, AKI acute kidney injury, CKD chronic kidney disease, IVC inferior vena cava, RIJ right internal jugular, TAMOF thrombocytopenia-associated multiorgan failure, DLC double-lumen catheter, eGFR estimated glomerular filtration rate vascular access (n=9) (four used 8 F; four 7 F; one 6 F), and three with congenital heart disease had 2×4 F single-lumen catheters. Median CRRT duration was 14.5 days (minimum 4 days; maximum 61 days; IQR=10, 22.8).
Prefilter convective clearance dose was initiated at 30 ml/ kg with Prismasol™ 2K/3.5 Ca plus 1 mEq/L KCL, 1 mEq/L KPhos, and 0.5 mEq/L magnesium sulfate. In CVVH, clearances of small and medium molecules are dependent on UF dose because the sieving coefficient of urea and other similar toxins approaches 1 (as opposed to hemodialysis, which is dependent on blood flow and treatment time). For this reason, we do not routinely perform formal clearance studies in infants on any CRRT device. Instead, we determine clearance by final effluent volume. Achieving metabolic control was obtained in all patients during the first few days of therapy and is shown in Fig. 2 as changes in blood urea nitrogen (BUN) and serum creatinine (SCr). There was one infant who had a rise in BUN; this was an anuric patient who, prior to Aquadex™ CVVH, was on CVVHDF in conjunction with extracorporeal membrane oxygenation at an effluent dose of 82 ml/kg/h. The reason for the rise in BUN was that once on Aquadex™, this patient was on lower prescribed clearance rates (30 ml/kg/h). Although the prescribing clinician had ample room to increase clearance (if clinically indicated) by simply increasing the prereplacement infusion dose, this was not necessary in any of the 12 patients. Even in children who were anuric during the CVVH course, SCr was typically between 0.8 and 1.2 mg/dl throughout the procedure.
Because during CRRT replacement fluid composition will approximate the patient's blood chemistries after equilibrium, we had no major issues with electrolytes. We achieved excellent metabolic control, and only very minor adjustments to fluid compositions were necessary. Figure 2c depicts sodium concentrations during the first 3 days of therapy for all 12 infants.
We used 101 circuits over 261 days (mean days/circuit= 2.6 ); 12 were initiated for a new start. Of the remaining 89, 12 (13.5 %) were planned discontinuations (seven were stopped due to patient issues, including discontinuation of cardiopulmonary support; four for elective therapeutic plasmapheresis; and one for trial off CVVH). Of the remaining 77, 54 (70 %) were stopped for routine change after 72 h; 15 (19.4 %) were stopped because of clotting issues, four (5 %) because of access issues, and four (5 %) due to system alarms.
Blood was used to prime 80/101 (79 %) circuits; all others were primed with saline. If a blood prime was used, circuits that lasted 72 h were cross-primed to reinitiate the next circuit (whereby blood from the running machine was used to prime the blood circuit of the new machine). We used 16.5 ml of blood for the blood prime (mixed 1:1 with sodium bicarbonate), and as per our policies and when available we used blood the infant was already exposed to. We found no episodes of thrombocytopenia, anemia, or coagulopathy associated with circuit initiation. Only five (5 %) circuit initiations were associated with an intervention to maintain blood pressure; of them, hemodynamic changes and the interventions needed were very mild (four had a <10 % increase in dopamine dose that they were already receiving, and one received 10 ml/kg 5 % albumin). One of these circuits was initiated with a saline prime, while the other four were blood-primed circuits. All of these patients had a prompt response to interventions. No patient had severe decompensation associated with circuit initiation.
Complications were few, considering that these patients are exposed to therapeutic risks 24 h a day. Hypothermia (as low as 35.2°C) occurred three times: the first was on the first infant placed on this therapy (before we started using an inline blood warmer); the second occurred when the patient was taken off the unit for a radiologic procedure without the in-line blood warmer; the third occurred when the in-line blood warmer was on but not appropriately set. The complication rate for hypothermia on any given day was 3/261 days=11 episodes/1000 patient-days.
Bleeding occurred in four patients: three had a small amount of bleeding from venous lines (which improved with , and serum sodium (c) levels on the day of initiation (day 1) and the following 2 days for the 12 patients on continuous venovenous hemofiltration (CVVH) using the adapted Aquadex™ circuit decreased heparin administration). One patient developed significant bleeding in his thoracic cavity. This was a heart transplant recipient who had an open chest, severe transplant rejection, was coagulopathic, thrombocytopenic, fungal sepsis, and a life-threatening inferior vena cava thrombus. His anticoagulation treatment was being managed by the cardiac intensive care team, which was treating him with aspirin and systemically applied heparin (target anti-Xa levels of 0.5 to 1.0 U/ml) for thrombus. The bleeding improved by stopping aspirin, providing fresh-frozen plasma/platelets, and decrease in heparin dose. No children developed intracerebral or pulmonary hemorrhage. The incidence of bleeding was 4/261= 15 episodes/1000 patient-days. In comparison, in the ppCRRT registry, 9/93 (10 %) patients receiving heparin anticoagulation developed significant bleeding (epistaxis, intracerebral, pulmonary, vaginal, or bladder hemorrhage); mild bleeding at venous sites was not documented.
Seven of the 12 (58 %) patients survived to come off renal support or were changed to peritoneal dialysis (n=2) for chronic therapy associated with end-stage renal disease. Of patients who survived, six (50 %) lived to hospital discharge; one patient died 6 months after CVVH and had an estimated glomerular filtration rate (eGFR) of 91 ml/min/1.73 m 2 prior to death. For those who died while on CRRT (n=5), their families elected to stop support for progressive pulmonary or cardiac failure. No child's therapy was discontinued due to the inability to perform CVVH or complications of the procedure. Although we did no formal fluid precision studies while these children received CVVH, we had no major concerns (i.e., excessive fluid loss or gain) in any patient.
In vitro tests
The median percent error rate for all 27 experiments was −1 % (maximum 4 %; minimum −9 %; IQR 1 %, −6 %). Figure 3a shows differences in percent error by replacement fluid rates (overall p value <0.001). There was a significant difference between 100 vs. 300 ml/h (p<0.01) and between 100 and 500 ml/h (p<0.01), but no difference was detected between 300 and 500 ml/h. Figure 3b shows differences by access pressures; no statistically significant differences were detected across pressures, nor were we ever concerned that excessive fluid removal was causing cardiovascular instability due to imprecise fluid removal.
Discussion
Here we report a case series of 12 patients who underwent CVVH over 261 days of therapy using the Aquadex™ machine adapted for CVVH. This procedure was performed in critically ill patients who otherwise would have not been able to receive renal support or would have been treated with a CRRT machine that had an ECV three times larger than the Aquadex™. We were able to support seven of the 12 infants long enough to come off CVVH, 6/7 (86 %) survived to hospital discharge; none died as a consequence of the renal failure or CVVH complication. Although difficult to attribute improved survival compared with other cohorts when using such a small sample size, survival rates were higher than reported in children <10 kg in the ppCRRT registry, which reported a 33 % survival rate [2] .
Compared with our experience using other circuits available in the United States, the most striking difference we observed with the adapted Aquadex™ system is the tremendous ease in getting these infants on circuit without the need for intensive cardiovascular, respiratory, and blood-product support. To our knowledge, the incidence of need to intervene with cardiopulmonary support during circuit initiation in small children has not been reported for those who are critically ill. However, as most pediatric nephrologists who have started CRRT on small infants can attest, the initiation procedure usually involves tremendous anxiety and a high risk of complications, particularly in critically ill infants and those whose percentage ECV/blood volume approaches ≥25 %. We certainly have been at the bedside on numerous occasions when cardiopulmonary resuscitation is initiated shortly after CRRT initiation. At our institution, prior to Aquadex™ adaptation, our policy dictated that two attendings be present at bedside and a concise plan of action for potential hypotension agreed upon before CRRT initiation in any small infant requiring a blood prime.
Although this machine greatly improved our ability to initiate therapy in this population, adaption of a machine designed for slow continuous UF as a CVVH device is not ideal, adds complexity, and is not without inherent risks. Several important improvements would enhance our ability to safely care for these small children. First, further reduction in circuit size could simplify the initiation process by allowing the use of a saline prime. At the current ECV of 33 ml, an infant <4 kg would receive a blood prime (for ECV of >10 %) according to our institutional guideline. A circuit volume <22 ml would allow all children in this case series to be primed with saline using our guidelines. Both the recently developed NIDUS [7] and CARPEDIEM™ [3] machines have circuit volumes within this range. The adapted system relies on a prereplacement IV fluid pump, which does not communicate with the Aquadex™ machine. Communication between the fluid-replacement pump, the heparin infusion pump, and UF pumps would greatly improve this system. Fourth, integration of a blood warmer into the machine would be ideal. Finally, exquisite precision of the pumps is greatly needed.
Other machines have been developed specifically for use in small children who need renal support therapy. These machines are currently being tested in Europe but are not available in the United States. The CARPEDIEM™ [3] and the NIDUS™ [7] have been designed specifically for renal support of newborns and have a smaller ECV than the Aquadex™: the NIDUS provides diffusive solute clearance, while the CARPEDIEM™ provides convective solute clearance. In addition, as opposed to the Aquadex™ system, infusion of replacement/diffusive fluids are incorporated into the machine. In 2014, the first report of an infant supported on CARPEDIEM™ was reported and as of November 2015, 34 infants have been supported on this therapy (verbal communication with Claudio Ronco). Meanwhile, 11 infants have been treated with the NIDUS™, with promising results. The NIDUS™ affords tremendous fluid precision (<0.25 % error) in a circuit that requires only 6.5 ml ECV and can be used with a single-lumen 4-F catheter. The CARPEDIEM™ can be used with filter sets as low as 23 ml and has fluid precision of ±7.5 % (which is close to the small in vitro tests we performed for Aquadex™). These systems have been designed for the small child and have great potential to alter the benefit/risk profile and change how we approach neonatal critical-care nephrology. Pediatric nephrologistsalongside industry partners, the FDA, and funding agencieswill need to work together to further develop these systems so they are available in the United States, providing practitioners with proper tools to care for these vulnerable little children.
Not only do we need machines specifically designed for small children, but the field of neonatal critical-care nephrology has many other questions that the community must answer to provide the necessary therapy. For example, we have found that a lower amount of heparin and lower targets for anticoagulation monitoring can be used within the described system. The NIDUS™ similarly uses lower ACT monitoring (~160-180). Determining the minimum amount of heparin necessary to maintain circuit patency is necessary. Having an alternate mode to provide regional (as opposed to systemic) anticoagulation could further reduce the risk. In addition, we and others have found that smaller access can be used for these smaller machines. We must work to better define the minimum access required for these small machines and ensure that the industry can provide an ample variety of catheters for different sized patients. It is likely that double-lumen catheters as small as 4 F will be sufficient to provide adequate flow for these machines [8] . Furthermore, and perhaps more importantly, large cohorts will be needed to determine which children will benefit from CRRT and what the appropriate time points are, especially as growing evidence suggest that early initiation improves outcomes [9, 10] . Finally, we need more data to assess whether using a small CVVH circuit (to bridge patients until they are ready to receive PD catheters) could yield better outcomes than trying to use PD catheters when they are at greater risk of leaking.
We acknowledge the limitations of this study. This case series relies on retrospective analysis of our clinical quality database and medical records. We relied on the ppCRRT registry in order to make comparisons, as it represents a similar cohort of critically ill patients who received CRRT; however, we cannot claim that survival improved in our cohort based on such a small sample size. In our program, we do not do formal urea clearance assessments of children on CVVH, as the sieving coefficient in CVVH is~1, and the clearance dose is closely related to the effluent volume (and hence, the prescribed replacement dose) monitoring. Although we provided data from in vitro laboratory tests, where we compared prescribed vs. actual fluid removed with this adapted system, we have not tested its precision in vivo. Even though we witnessed no severe cardiovascular changes attributable to imprecise fluid removal rates, we recommend that additional measures be considered (e.g., twice-daily weight measurement) when using these types of adapted systems in order to ensure that excess fluid is not being delivered or removed.
In conclusion, we present data suggesting that performing CRRT in small children using a machine with small ECV can improve the care of infants who need renal support therapy by providing a safer ability to initiate therapy. We initiated therapy without the need for major interventions, even in critically ill children with significant cardiac disease and who required extensive cardiopulmonary support. The pediatric nephrology community will need to work closely with funding agencies, regulatory agencies and industry to bring these machines to the bedside so that renal support therapy with minimal risk can be timely provided to even the smallest infants.
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